Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study

J V Jovanovic, A Ivey, A M Vannucchi, E Lippert, E Oppliger Leibundgut, B Cassinat, N Pallisgaard, N Maroc, S Hermouet, G Nickless, P Guglielmelli, B A van der Reijden, J H Jansen, T Alpermann, S Schnittger, A Bench, K Tobal, B Wilkins, K Cuthill, D McLornanK Yeoman, S Akiki, J Bryon, S Jeffries, A Jones, M J Percy, S Schwemmers, A Gruender, T W Kelley, S Reading, A Pancrazzi, M F McMullin, H L Pahl, N C P Cross, C N Harrison, J T Prchal, C Chomienne, J J Kiladjian, T Barbui, D Grimwade

Research output: Contribution to journal › Article › peer-review

73 Citations (Scopus)
176 Downloads (Pure)

Fingerprint

Dive into the research topics of 'Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study'. Together they form a unique fingerprint.

Medicine & Life Sciences